Bank of New York Mellon Corp purchased a new position in Biohaven Ltd. (NYSE:BHVN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 386,939 shares of the company's stock, valued at approximately $5,758,000. Bank of New York Mellon Corp owned approximately 0.26% of Biohaven at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in shares of Biohaven by 49.4% during the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company's stock valued at $2,761,000 after purchasing an additional 37,981 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company's stock worth $1,747,000 after buying an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company's stock worth $14,174,000 after buying an additional 41,040 shares during the last quarter. Intech Investment Management LLC increased its position in Biohaven by 80.3% during the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company's stock valued at $1,481,000 after buying an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company's stock valued at $125,000 after buying an additional 8,102 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.
Biohaven Stock Down 1.1%
BHVN stock opened at $15.69 on Friday. The business's 50-day moving average price is $14.86 and its 200-day moving average price is $12.01. The stock has a market cap of $2.37 billion, a P/E ratio of -3.38 and a beta of 1.28. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23. Biohaven Ltd. has a twelve month low of $7.48 and a twelve month high of $18.57.
Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, equities research analysts forecast that Biohaven Ltd. will post -3.3 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on BHVN. HC Wainwright reissued a "neutral" rating on shares of Biohaven in a research note on Thursday, August 27th. Morgan Stanley lifted their price target on Biohaven from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Biohaven from a "strong sell" rating to a "sell" rating in a report on Saturday, June 27th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Biohaven in a research note on Friday, June 26th. Finally, Royal Bank Of Canada increased their price target on shares of Biohaven from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.94.
Get Our Latest Analysis on BHVN
Biohaven Profile
(
Free Report)
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
